RESVERLOGIX CORP (RVX.CA) Stock Overview
Canada - TSX:RVX - CA76128M1086 - Common Stock
RVX.CA Key Statistics, Chart & Performance
The current stock price of RVX.CA is 0.095 CAD. In the past month the price increased by 5.56%. In the past year, price increased by 46.15%.
RVX.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| EDT.CA | SPECTRAL MEDICAL INC | N/A | 443.43M | ||
| EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 387.09M | ||
| FRX.CA | FENNEC PHARMACEUTICALS INC | N/A | 352.61M | ||
| HBP.CA | HELIX BIOPHARMA CORP | N/A | 159.63M | ||
| MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 131.79M | ||
| NRX.CA | NUREXONE BIOLOGIC INC | N/A | 60.23M | ||
| COV.CA | COVALON TECHNOLOGIES LTD | 27.25 | 59.78M | ||
| BCT.CA | BRIACELL THERAPEUTICS CORP | N/A | 36.02M | ||
| MBX.CA | MICROBIX BIOSYSTEMS INC | N/A | 34.18M | ||
| HEM.CA | HEMOSTEMIX INC | N/A | 18.40M | ||
| CSCI.CA | COSCIENS BIOPHARMA INC | N/A | 11.41M | ||
| QPT.CA | QUEST PHARMATECH INC | N/A | 6.77M |
Related stock screener links
About RVX.CA
Company Profile
Resverlogix Corp. engages in the research and development of pharmaceutical products for cardiovascular diseases. The company is headquartered in Calgary, Alberta and currently employs 18 full-time employees. The company went IPO on 2001-10-12. The firm focuses on the development of a new class of therapeutics: bromodomain and extraterminal domain (BET) protein inhibitors. BET proteins play a central role in epigenetics and enable the transcription of disease-causing genes. Its small molecule BET inhibitors are designed to exploit this central epigenetic role to regulate gene expression and tackle the root causes of chronic diseases. The firm's clinical program focuses on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post-COVID-19 conditions. The company partners with EVERSANA to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
Company Info
RESVERLOGIX CORP
300-4820 Richard Rd SW
Calgary ALBERTA T3E 6L1 CA
CEO: Donald J. McCaffrey
Employees: 18
Phone: 14032549252
RESVERLOGIX CORP / RVX.CA FAQ
What does RESVERLOGIX CORP do?
Resverlogix Corp. engages in the research and development of pharmaceutical products for cardiovascular diseases. The company is headquartered in Calgary, Alberta and currently employs 18 full-time employees. The company went IPO on 2001-10-12. The firm focuses on the development of a new class of therapeutics: bromodomain and extraterminal domain (BET) protein inhibitors. BET proteins play a central role in epigenetics and enable the transcription of disease-causing genes. Its small molecule BET inhibitors are designed to exploit this central epigenetic role to regulate gene expression and tackle the root causes of chronic diseases. The firm's clinical program focuses on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post-COVID-19 conditions. The company partners with EVERSANA to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
What is the stock price of RESVERLOGIX CORP today?
The current stock price of RVX.CA is 0.095 CAD.
What is the dividend status of RESVERLOGIX CORP?
RVX.CA does not pay a dividend.
What is the ChartMill technical and fundamental rating of RVX stock?
RVX.CA has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Where is RESVERLOGIX CORP (RVX.CA) stock traded?
RVX.CA stock is listed on the Toronto Stock Exchange exchange.
How many employees does RESVERLOGIX CORP have?
RESVERLOGIX CORP (RVX.CA) currently has 18 employees.
RVX.CA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to RVX.CA. When comparing the yearly performance of all stocks, RVX.CA turns out to be only a medium performer in the overall market: it outperformed 46.86% of all stocks.
RVX.CA Financial Highlights
Over the last trailing twelve months RVX.CA reported a non-GAAP Earnings per Share(EPS) of -0.06. The EPS increased by 12.03% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -143.27% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |